Compare Adaptive Biotechnologies Corp (ADPT) vs Expedia Group Inc (EXPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Expedia Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Expedia Group Inc trades at $259.51 (market cap $32.39B). The key difference: Expedia Group Inc is far larger — about 9.7× Adaptive Biotechnologies Corp's market cap, and Expedia Group Inc pays a 0.65% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | EXPE | |
|---|---|---|
Market Cap | $3.33B | $32.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $301.31 |
52-Week Low | $10.24 | $176.09 |
Enterprise Value | $3.19B | $31.30B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Expedia Group (EXPE) trades at $269.87, up 0.44% with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported consistent earnings beats in recent quarters with Q1 2026 EPS of $1.96 exceeding expectations of $1.41. Revenue growth has been steady, climbing from $11.7B in 2022 to $14.7B in 2025, while maintaining robust profitability with a 90.27% gross margin. Recent developments include the CarTrawler acquisition and positive travel industry research positioning the company for continued growth.
EXPE presents a compelling investment case with analyst consensus price target of $281.75 representing 4.4% upside potential. The stock offers exposure to the resilient travel sector with improving operational efficiency and strong cash flow generation. Key risks include travel sector volatility and competitive pressures, but the company's technological innovation and market position provide defensive characteristics in the evolving travel landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
